Dr. Syed M. Rizvi, MD

Dr. Rizvi practices at WellSpan Waynesboro Hospital in Waynesboro, Pennsylvania, part of WellSpan Health.

Dr. Rizvi's NPI, 1568619237, was assigned on August 25, 2008. Dr. Rizvi graduated from UT Southwestern Medical Center in 2021. Dr. Rizvi's Texas license number on file is R0113.

Dr. Rizvi's primary practice is WellSpan Waynesboro Hospital, at 501 East Main St, Waynesboro, PA 17268 in Franklin County. The practice phone is (717) 765-4000.

Dr. Rizvi's primary practice is WellSpan Waynesboro Hospital in Waynesboro, Pennsylvania, part of WellSpan Health. Dr. Rizvi is also affiliated with William P. Clements Jr. University Hospital. The medical group on file is WellSpan Urology - Lebanon. Dmand AI also links Dr. Rizvi to 2 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rizvi practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rizvi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rizvi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Rizvi's licenses on file in 6 states: Texas, Illinois, Pennsylvania, Florida, Minnesota and Nebraska.

CMS data shows 78 Medicare services from Dr. Rizvi across 3 procedure codes in 2024, for 80 Medicare patients. Medicare paid $8,080 for them. Every service was in an office.

CMS counts 80 Medicare patients who saw Dr. Rizvi in 2024. The largest group is 65 to 74, with 29 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rizvi's median patient age at 58, with 64% women.

In 2022, Dr. Rizvi wrote 119 Medicare Part D claims. Every claim was for a generic drug. They cover 5 drugs, with $1,889 in total drug cost. In 2021, CMS named 82 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Rizvi for performance year 2024, reported as part of a group. Dr. Rizvi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rizvi as offering telehealth.

Dmand AI links 2 papers to Dr. Rizvi, published from 2018 to 2024. Dr. Rizvi's most frequent co-authors are Michael G. Bayerl, MD, David F. Claxton, MD and Raymond J. Hohl, MD.

CMS Open Payments shows 26 general payments to Dr. Rizvi from 8 drug and device companies from 2017 to 2024. Consulting fees make up the largest share, 70% of the total. Sanofi and Genzyme US Companies paid the most, $4,020.

Dr. Rizvi graduated from UT Southwestern Medical Center in 2021.

Dr. Rizvi is in network with 21 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.